Surya Narayan Patra · PhillipCapital
partialUpdate on GLP-1 capacity buildup and pilot plant commercialization.
So on GLP-1s, okay, we have already like I explained last time, we have already completed construction of a pilot plant. We have also completed one of our commercial buildings, which has several large-scale SPPSs, which is basically designed based on one of our customer's requirements. So I'm not at the liberty to speak about capacity created, but the validations are going on as we speak right now because pilot work is done. Now it's moving towards validations.
Surya Narayan Patra · PhillipCapital
evasiveAre the three dedicated CS facilities related to peptides?
I cannot comment on that, but what I can tell you is it's a mixture of everything. It's also in chemistry. There are several projects which are involved in it.
Surya Narayan Patra · PhillipCapital
partialCapacity utilization and progress on contrast media opportunities.
So I mean, just to generalize because you spoke about several segments, okay, capacity utilization, we are about 70%-80% of capacity utilization right now. Depending on the month, and sometimes you're at 80%-85%, sometimes you're at 70%, depends on when the shipments would be happening.
Tushar Manudhane · Motilal Oswal Financial Services
directClarification on CS molecules moving to commercial volumes and timeline.
All I can say is once the validations are completed and some are already completed, we are waiting for all regulatory approvals, after which the volumes would be discussed for commercialization. So that is what we're expecting to happen in the next one year.
Tushar Manudhane · Motilal Oswal Financial Services
directHedging policy for export exposure.
We are not hedging. We are evaluating at this point based on the overall scenario in the market.
Tushar Manudhane · Motilal Oswal Financial Services
directWhy limited growth in generic API despite stable raw materials?
See, the generic space, the pricing pressures are still continuing. We haven't mentioned that the pricing have eased. We did mention that the pricing pressures are still continuing. But if we look at generics, we need to see one is the value and another is the volume. As a volume, we have had a good growth. But it's just that because of the pricing pressures, value-wise, it doesn't reflect in that manner.
Kunal Dhamesha · Macquarie
partialDrivers of sharp gross margin improvement in Q3.
I would say it's mainly based on the product mix. As you can see, the CS has improved in the nine-month period as compared to the previous nine months. So it's mainly to do with the product mix rather than anything else.
Kunal Dhamesha · Macquarie
declinedProportion of commercializing molecules that are already approved vs new.
I'm sorry. I cannot answer this question because we are bound by CDA. I cannot disclose their plans and at what stages any of our customers are.
Neha Manpuria · BofA
directTimeline for commissioning of dedicated CapEx announced in 2024.
By 2027, we should start seeing commercialization post our customers they start approving the product.
Neha Manpuria · BofA
partialImpact of China's export rebate withdrawal on generic API portfolio.
I didn't mention that with respect to the APIs. I said with respect to procurement of materials. So the withdrawal of export tax rebates has taken place and will be from April 1st. We are wary of the situation... we have increased our domestic supplier base to 78% of the procurement.
Vivek Agarwal · Citi
evasiveWill the dedicated peptide building be sufficient for 4-5 years?
So as and when we have demand, we will keep increasing capacity or building new blocks whenever the demand and question arises. For this customer, what we have dedicated, it is based on what his requirement and his designs are. I'm not at any other liberty to discuss on that.
Shyam Srinivasan · Goldman Sachs
directGrowth outlook for next 12 months given key product going generic.
We do not see any; we do not foresee any disruption because, and it's in line with whatever our double-digit growth that we keep talking about. ... We always have a nice, decent balance of equilibrium while our growth trajectory is actually happening at the double-digit.
